T1	Participants 79 94	healthy adults:
T2	Participants 565 629	Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
T3	Participants 630 684	Participants (aged 18-65 years) were randomly assigned
T4	Participants 745 817	individuals potentially deployed in endemic areas and those not deployed
T5	Participants 1566 1578	NCT02289027.
T6	Participants 1579 1816	FINDINGS Between Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo
